Fibrinogen TRIZ Cases

An Fc-linked citrullinated fibrin peptide targets ACPA-positive B cells for immune clearance, aiming to reduce chronic rheumatoid inflammation.

Micropore filtration and staged separation recover intact cord blood exosomes and plasma proteins for xeno-free cell culture media.

A 17-20 nt guide RNA directs CRISPR to disable the mutated FGA allele while preserving the functional copy to prevent amyloid formation.

Engineered fibrinogen variants alter plasmin cleavage sites to extend sealant stability without aprotinin-related allergy risk.

A 3D microfluidic chip recreates the RPE-choroid interface with perfusable vessels and hydrogel to support AMD studies and drug response analysis.

This case combines Arabidopsis 5′ UTRs, optimized codons, 3′ UTRs, and modified nucleotides for stable protein expression.

Fibrinogen peptide fragments block P. acnes adhesion, reducing inflammation without antibiotic side effects.

Weak base anion exchangers purify fibrinogen and Factor XIII from solubilized plasma, eliminating metal contamination risks from traditional affinity gels.

Thiol-ene click chemistry modifies proteins rapidly without harsh conditions, preventing damage and side reactions.

Adding fibrinogen to liquid D-dimer buffers extends shelf life to 24 weeks at 37°C, avoiding lyophilization complexity.

Sequential glycine precipitation removes insoluble impurities before nanofiltration, resolving low efficiency in virus removal.

Fibrinogen-420 acts as a molecular chaperone to refold denatured proteins and stabilize their conformation.

Replacing ethanol with polyacids eliminates complex temperature control and solvent hazards while maintaining high protein recovery rates.

Multi-step chromatography purifies fibrinogen and thrombin from human plasma using sequential gel filtration, hydrophobic interaction, and ion exchange columns.

A rotor-stator disperser washes ethanol precipitates to remove contaminant proteins without mechanical degradation during plasma treatment.

Codon-adapted nucleotide sequences boost intact fibrinogen yield and purity in mammalian cells, eliminating the need for protease inhibitors.

Recombinant tropoelastin blends with synthetic polymers create stable protoelastin films that support endothelial cell adhesion.

Nonpolymerizable fibrinogen suppresses fibrin matrix formation, reducing thrombosis risk without compromising hemostatic function.

Local delivery of bioactive factors via a crosslinked matrix increases bone density while avoiding systemic treatment limitations.

Chelating agents prevent fibrinogen aggregation during precipitation, enabling effective nanofiltration while minimizing pathogen contamination risks.

Decellularized vascular extracellular matrix forms a hydrogel substrate that promotes vasculogenesis and tissue repair.

A fibrinogen-based tissue adhesive patch incorporates sealant into a biocompatible polymer backing to attach the device to affected tissue.

Sequential coupling of protected amino acids builds eptifibatide resin, avoiding impurities like [+1Gly]-eptifibatide to achieve over 99.5% purity.

A hemostatic device uses a dissolvable coating to enclose and release clotting agents at the wound site.

Reintroducing plasma proteins into purified fibrinogen restores formulation stability lost during concentration.

Peptides inhibit soluble fibrin binding to restore cytotoxicity and reduce metastasis.

Grafting a hybrid molecule onto immune cells eliminates ACPA-positive B lymphocytes, addressing the lack of curative rheumatoid arthritis treatments.